Ferric citrate to reduce heart failure in patients with chronic kidney disease

摘要

PROBLEM TO BE SOLVED: To lower and / or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters, increase iron absorption, and increase iron storage in patients with chronic kidney disease. Maintain, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis stimulants, and / or reduce mortality and morbidity associated with adverse cardiac events Providing a way to make it. SOLUTION: A therapeutic agent containing ferric citrate, which reduces the mortality and morbidity associated with adverse heart events in human patients with end-stage kidney disease, and the therapeutic agent is 6 g per day. The ferric citrate is used to be orally administered to the patient in an amount in the range of ~ 12 g for at least 52 weeks, the patient having elevated FGF-23 levels of the ferric citrate. Administration reduces FGF-23 levels in the patient. [Selection diagram] None